S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
The Day of Financial Reckoning Is Near (Ad)
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
The ONLY Way to Play Markets Like These (Ad)pixel
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The ONLY Way to Play Markets Like These (Ad)pixel
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
The Day of Financial Reckoning Is Near (Ad)
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
The ONLY Way to Play Markets Like These (Ad)pixel
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The ONLY Way to Play Markets Like These (Ad)pixel
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
The Day of Financial Reckoning Is Near (Ad)
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
The ONLY Way to Play Markets Like These (Ad)pixel
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The ONLY Way to Play Markets Like These (Ad)pixel
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
S&P 500   4,228.48
DOW   33,706.74
QQQ   322.86
Apple’s Stock Could Be On The Verge Of Another 30% Rally
The Day of Financial Reckoning Is Near (Ad)
2 Russian villages evacuated after fire at munitions depot
Near-Term Headwinds Present An Opportunity In Ross Stores
The ONLY Way to Play Markets Like These (Ad)pixel
Global markets lower after Wall Street gains on jobs data
Stocks fall broadly, S&P 500 set to break winning streak
The ONLY Way to Play Markets Like These (Ad)pixel
Closing prices for crude oil, gold and other commodities
Yangtze shrinks as China's drought disrupts industry
NASDAQ:BPMC

Blueprint Medicines - BPMC Stock Forecast, Price & News

$69.66
+5.57 (+8.69%)
(As of 08/19/2022 12:00 AM ET)
Add
Compare
Today's Range
$63.29
$70.20
50-Day Range
$45.23
$72.22
52-Week Range
$43.46
$117.86
Volume
1.39 million shs
Average Volume
786,104 shs
Market Capitalization
$4.15 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$90.27

Blueprint Medicines MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.54 Rating Score
Upside/​Downside
29.6% Upside
$90.27 Price Target
Short Interest
Bearish
9.13% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.24mentions of Blueprint Medicines in the last 14 days
Based on 25 Articles This Week
Insider Trading
Selling Shares
$2.33 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.18) to ($7.99) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.15 out of 5 stars

Medical Sector

563rd out of 1,116 stocks

Pharmaceutical Preparations Industry

273rd out of 545 stocks

BPMC stock logo

About Blueprint Medicines (NASDAQ:BPMC) Stock

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of non-advanced SM and other mast cell disorders; and Fisogatinib, an orally available and potent inhibitor for the treatment of hepatocellular carcinoma. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered solid tumors, medullary thyroid carcinoma, and other solid tumors; BLU-701 and BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.

Analysts Set New Price Targets

A number of research firms recently issued reports on BPMC. Citigroup downgraded Blueprint Medicines from a "neutral" rating to a "sell" rating and lowered their target price for the company from $68.00 to $41.00 in a research report on Thursday, June 9th. Piper Sandler lowered their target price on shares of Blueprint Medicines from $65.00 to $59.00 in a report on Tuesday, August 2nd. The Goldman Sachs Group increased their price target on shares of Blueprint Medicines from $126.00 to $143.00 and gave the company a "buy" rating in a research note on Wednesday, August 3rd. Raymond James lowered their price objective on shares of Blueprint Medicines from $133.00 to $115.00 and set a "strong-buy" rating on the stock in a research note on Wednesday, August 3rd. Finally, Morgan Stanley cut their target price on shares of Blueprint Medicines from $92.00 to $65.00 and set an "equal weight" rating for the company in a research note on Tuesday, June 14th. Two research analysts have rated the stock with a sell rating, four have given a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat, Blueprint Medicines presently has an average rating of "Moderate Buy" and an average price target of $90.27.

Blueprint Medicines Stock Performance

Shares of BPMC Stock traded up $5.57 on Friday, hitting $69.66. The company's stock had a trading volume of 1,391,041 shares, compared to its average volume of 786,103. Blueprint Medicines has a fifty-two week low of $43.46 and a fifty-two week high of $117.86. The stock's 50 day moving average is $55.94 and its 200-day moving average is $61.05. The company has a market capitalization of $4.15 billion, a PE ratio of -5.88 and a beta of 0.94.

Blueprint Medicines (NASDAQ:BPMC - Get Rating) last announced its earnings results on Tuesday, August 2nd. The biotechnology company reported ($2.68) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($2.23) by ($0.45). Blueprint Medicines had a negative return on equity of 45.89% and a negative net margin of 304.41%. The business had revenue of $36.55 million for the quarter, compared to analyst estimates of $37.61 million. During the same quarter in the previous year, the company earned ($1.86) EPS. The business's revenue for the quarter was up 33.9% on a year-over-year basis. On average, research analysts forecast that Blueprint Medicines will post -9.18 earnings per share for the current year.

Insiders Place Their Bets

In other news, SVP Christopher K. Murray sold 2,500 shares of the company's stock in a transaction on Thursday, August 4th. The stock was sold at an average price of $60.44, for a total transaction of $151,100.00. Following the completion of the sale, the senior vice president now directly owns 21,320 shares in the company, valued at approximately $1,288,580.80. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In related news, Director Jeffrey W. Albers sold 10,000 shares of the stock in a transaction that occurred on Monday, August 8th. The shares were sold at an average price of $70.07, for a total transaction of $700,700.00. Following the sale, the director now owns 183,243 shares in the company, valued at approximately $12,839,837.01. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Christopher K. Murray sold 2,500 shares of the business's stock in a transaction that occurred on Thursday, August 4th. The shares were sold at an average price of $60.44, for a total transaction of $151,100.00. Following the transaction, the senior vice president now owns 21,320 shares of the company's stock, valued at $1,288,580.80. The disclosure for this sale can be found here. Insiders have sold a total of 34,408 shares of company stock worth $2,334,022 in the last 90 days. Company insiders own 3.42% of the company's stock.

Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Stock News Headlines

Blueprint Medicines (NASDAQ:BPMC) Price Target Cut to $80.00
See More Headlines
Receive BPMC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Blueprint Medicines and its competitors with MarketBeat's FREE daily newsletter.

BPMC Company Calendar

Last Earnings
8/02/2022
Today
8/19/2022
Next Earnings (Estimated)
10/27/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BPMC
Fax
N/A
Employees
495
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$90.27
High Stock Price Forecast
$152.00
Low Stock Price Forecast
$40.00
Forecasted Upside/Downside
+29.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.54
Research Coverage
13 Analysts

Profitability

Net Income
$-644,090,000.00
Net Margins
-304.41%
Pretax Margin
-301.76%

Debt

Sales & Book Value

Annual Sales
$180.08 million
Book Value
$12.55 per share

Miscellaneous

Free Float
57,534,000
Market Cap
$4.15 billion
Optionable
Optionable
Beta
0.94

Key Executives

  • Mr. Jeffrey W. Albers J.D.Mr. Jeffrey W. Albers J.D. (Age 51)
    M.B.A., MBA, Exec. Chairman
    Comp: $1.38M
  • Ms. Kathryn Haviland (Age 46)
    Pres, CEO & Director
    Comp: $786.39k
  • Mr. Alexis A. Borisy A.M. (Age 50)
    Co-Founder & Director
    Comp: $46.64k
  • Mr. Michael Landsittel (Age 50)
    Chief Financial Officer
    Comp: $679.05k
  • Dr. Percy H. Carter M.B.A. (Age 51)
    Ph.D., Chief Scientific Officer
    Comp: $761.15k
  • Dr. Fouad Namouni M.D.Dr. Fouad Namouni M.D. (Age 53)
    Pres of R&D
    Comp: $986.52k
  • Ms. Christina RossiMs. Christina Rossi (Age 46)
    Chief Operating Officer
  • Dr. Christopher K. Murray (Age 59)
    Sr. VP of Technical Operations
  • Jenna Cohen
    Sr. Director & Head of Investor Relations
  • Ms. Tracey L. McCain Esq. (Age 54)
    Exec. VP, Chief Legal & Compliance Officer and Sec.













BPMC Stock - Frequently Asked Questions

Should I buy or sell Blueprint Medicines stock right now?

13 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 2 sell ratings, 3 hold ratings, 7 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BPMC shares.
View BPMC analyst ratings
or view top-rated stocks.

What is Blueprint Medicines' stock price forecast for 2022?

13 Wall Street research analysts have issued 1-year target prices for Blueprint Medicines' shares. Their BPMC share price forecasts range from $40.00 to $152.00. On average, they predict the company's share price to reach $90.27 in the next twelve months. This suggests a possible upside of 29.6% from the stock's current price.
View analysts price targets for BPMC
or view top-rated stocks among Wall Street analysts.

How have BPMC shares performed in 2022?

Blueprint Medicines' stock was trading at $107.11 at the beginning of the year. Since then, BPMC shares have decreased by 35.0% and is now trading at $69.66.
View the best growth stocks for 2022 here
.

When is Blueprint Medicines' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, October 27th 2022.
View our BPMC earnings forecast
.

How were Blueprint Medicines' earnings last quarter?

Blueprint Medicines Co. (NASDAQ:BPMC) released its quarterly earnings data on Tuesday, August, 2nd. The biotechnology company reported ($2.68) EPS for the quarter, missing analysts' consensus estimates of ($2.23) by $0.45. The biotechnology company had revenue of $36.55 million for the quarter, compared to the consensus estimate of $37.61 million. Blueprint Medicines had a negative net margin of 304.41% and a negative trailing twelve-month return on equity of 45.89%. The company's quarterly revenue was up 33.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($1.86) earnings per share.

What guidance has Blueprint Medicines issued on next quarter's earnings?

Blueprint Medicines issued an update on its FY 2022 earnings guidance on Tuesday, August, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $180.00 million-$200.00 million, compared to the consensus revenue estimate of $194.85 million.

What is Kate Haviland's approval rating as Blueprint Medicines' CEO?

16 employees have rated Blueprint Medicines Chief Executive Officer Kate Haviland on Glassdoor.com. Kate Haviland has an approval rating of 100% among the company's employees. This puts Kate Haviland in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. 93.0% of employees surveyed would recommend working at Blueprint Medicines to a friend.

What other stocks do shareholders of Blueprint Medicines own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), NVIDIA (NVDA), AbbVie (ABBV), Micron Technology (MU), Pfizer (PFE), Gilead Sciences (GILD), QUALCOMM (QCOM), Amarin (AMRN), CRISPR Therapeutics (CRSP) and Nektar Therapeutics (NKTR).

When did Blueprint Medicines IPO?

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

What is Blueprint Medicines' stock symbol?

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Who are Blueprint Medicines' major shareholders?

Blueprint Medicines' stock is owned by many different institutional and retail investors. Top institutional investors include FMR LLC (14.40%), Price T Rowe Associates Inc. MD (9.45%), State Street Corp (4.56%), JPMorgan Chase & Co. (2.89%), Macquarie Group Ltd. (2.14%) and Casdin Capital LLC (1.93%). Insiders that own company stock include Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, Christina Rossi, Christopher K Murray, Debra Durso-Bumpus, Fouad Namouni, George Demetri, Jeffrey W Albers, Kate Haviland, L Becker Hewes, Marion Dorsch, Mark Alan Goldberg, Nicholas Lydon, Percy H Carter and Tracey L Mccain.
View institutional ownership trends
.

How do I buy shares of Blueprint Medicines?

Shares of BPMC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Blueprint Medicines' stock price today?

One share of BPMC stock can currently be purchased for approximately $69.66.

How much money does Blueprint Medicines make?

Blueprint Medicines (NASDAQ:BPMC) has a market capitalization of $4.15 billion and generates $180.08 million in revenue each year. The biotechnology company earns $-644,090,000.00 in net income (profit) each year or ($11.87) on an earnings per share basis.

How many employees does Blueprint Medicines have?

The company employs 495 workers across the globe.

How can I contact Blueprint Medicines?

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The official website for the company is www.blueprintmedicines.com. The biotechnology company can be reached via phone at (617) 374-7580 or via email at ir@blueprintmedicines.com.

This page (NASDAQ:BPMC) was last updated on 8/20/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.